Article
Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
Bone - 1 Aug 2013
Napoli Nicola, Rastelli Antonella, Ma Cynthia, Yarramaneni Jayasree, Vattikutti Swapna, Moskowitz Gerard, Giri Tusar, Mueller Cheryl, Kulkarny Vibhati, Qualls Clifford, Ellis Matthew, Armamento-Villareal Reina
Abstract excerpt
PURPOSE: Polymorphisms in the CYP19A1 (aromatase) gene have been reported to influence disease-free survival and the incidence of musculoskeletal complaints in patients taking aromatase inhibitors (AIs) for estrogen receptor positive (ER+) breast cancer. Bone loss and fractures are well-recognized complications from AI therapy. The objective of this study is to determine the influence of polymorphisms in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
